CLYM vs SYRE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 24, 2026

CLYM

33.3
AI Score
VS
SYRE Wins

SYRE

46.9
AI Score

Investment Advisor Scores

CLYM

33score
Recommendation
SELL

SYRE

47score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CLYM SYRE Winner
Net Income -27.22M -155.20M CLYM
Operating Income -30.57M -209.56M CLYM
ROE -11.4% -21.7% CLYM
ROA -11.1% -20.0% CLYM
Total Assets 246.29M 777.78M SYRE
Cash 44.11M 85.72M SYRE
Current Ratio 31.45 13.25 CLYM

Relative Price Performance (Last 90 Days)

CLYM 1M: +27.7% · 3M: +49.1% SYRE 1M: +4.4% · 3M: +44.0%

Current Technical Phase

CLYM

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (11.8% over 20 days), RSI 64

RSI (14): 64.4 · Price: $16.40

SYRE

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (14.1% over 20 days), RSI 58

RSI (14): 58.1 · Price: $106.65

Fundamentals Snapshot

Metric CLYM SYRE
Market Cap
Forward P/E -15.5 -31.0
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin
Operating Margin 0.0% 0.0%
EPS -0.82 -1.92
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, SYRE is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.